Novaremed Secures Additional Financing and Strengthens Leadership
2.9.2019 12:38:00 EEST | Business Wire | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has secured CHF2.6 million in additional financing from its existing shareholders and several new private investors. This brings the total financing raised by the company, since its inception, to CHF21 million. In addition, the company announced that Subhasis Roy, Novaremed’s COO since April 2018, will be stepping up and fulfilling the role of Interim CEO.
The recent funding and strengthened leadership team are both integral developments for Novaremed as the company accelerates its preparation towards initiating a Phase 2b study in Diabetic Neuropathic Pain (DNP). The company is pleased to have received positive feedback from the FDA from their recently conducted Pre-IND meeting, which sets the path forward for the IND opening of the Phase 2b study in DNP.
"This additional financing underscores the commitment of our shareholders and private investors, as well as their faith in Novaremed’s potential," said Harry Welten, Chairman of the Board of Novaremed. "Novaremed is well-positioned with a seasoned leadership team, led by Subhasis, to drive Novaremed’s clinical development and operations forward."
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and transferred its corporate headquarters to Novaremed AG, founded in November 2017 in Switzerland. Novaremed is developing NRD.E1, an orally active non-opioid small molecule with a new mechanism of action for the treatment of DNP. In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DNP, expected to start in Q2/3 2020. For more information, visit www.novaremed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190902005074/en/
Contact information
Subhasis Roy, Interim CEO/COO
Tel: +41 79 2075715
Email:
subhasis.roy@novaremed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Resident Evil Veronica to Launch in 2027!8.6.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Veronica, the latest title in the Resident Evil series, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608994346/en/ Resident Evil Veronica key art The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to survive terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 201 million* units. Resident Evil Veronica is a remake of the original Resident Evil Code: Veronica, released in the year 2000. While preserving the appeal of the original, Capcom is developing the 2027 release as the latest installment of the Resident Evil series, with a reimagined story and high-quality graphics made possible by the company’s proprietary RE ENGINE. The company is steadily develo
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization8.6.2026 16:00:00 EEST | Press release
Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. Wiinberg’s experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth’s Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acquired by Pfizer. Ulf serves as a director on several company boards including UCB, a global biopharmaceutical company headquartered in Brussels,
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Further details will be announced in future official updates. The Monster Hunter series has expanded its user base globally t
AB InBev Turns Bars into Stadiums During Biggest-Ever FIFA World Cup™8.6.2026 15:00:00 EEST | Press release
Today, AB InBev, the world’s leading brewer, launched its global “Cheers to Bars” platform – a celebration of local bars and their impact on communities all over the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608956519/en/ Bars have always been more than places to grab a beer. They are where people come together to connect, celebrate milestones, build friendships, and create lasting memories. As hubs of social connection, bars play an important role in strengthening communities and bringing people closer together. “During the FIFA World Cup 2026™, bars will become the beating heart of every neighborhood – places where strangers become friends, every goal is celebrated as one, and collective memories are created with every raised glass,” said Michel Doukeris, CEO, AB InBev. “Beer and football have long been catalysts for bringing people together to create moments of joy and belonging. Nowhere is this spirit of b
Seequent and Cascade Institute Partner to Map Canada’s Deep Geothermal Resources8.6.2026 15:00:00 EEST | Press release
Seequent, The Bentley Subsurface Company, and the Cascade Institute today announced a collaboration to develop a Canadian Thermal Model. This landmark national initiative will reveal Canada’s deep geothermal resources and accelerate the development of renewable energy. The announcement comes on the opening day of the world’s biggest geothermal event, the World Geothermal Congress, being held in Calgary from 8 to 11 June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608741816/en/ The Canadian Thermal Model will integrate over 20 input layers of geoscientific data related to geothermal energy to evaluate Canada’s nationwide deep heat resources. As investment in geothermal energy surges globally as a reliable, always-on clean power source, the Canadian Thermal Model will create a comprehensive national view of deep heat resources using novel machine learning methods to address a long-standing challenge for the sector: limi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom